Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370828 | 0.89 | GAA (0.43) | GAAMAPK1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL13214510 | 0.87 | SLC6A3 (0.44) | GAAMAPK1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL363529 | 0.87 | S1PR3 (0.39) | GAAMAPK1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3013426 | 0.84 | S1PR3 (0.40) | GAAMAPK1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL370827 | 0.82 | GAA (0.43) | GAAMAPK1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL13183846 | 0.81 | CA12 (0.43) | GAAMAPK1KMT2ABRD4SMN1; SMN2 | |
| SCHEMBL1390375 | 0.81 | SMN1; SMN2 (0.42) | GAAMAPK1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL10363351 | 0.80 | GAA (0.45) | GAAMAPK1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL490341 | 0.80 | SMN1; SMN2 (0.53) | GAAMAPK1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL28783966 | 0.80 | KMT2A (0.49) | MAPK1KMT2ABRD4SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-9283226-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-15 | — | — | US | disclosed |
| US-9283226-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-15 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| US-8691806-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2014-04-08 | — | — | US | disclosed |
| US-8691806-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2014-04-08 | — | — | US | disclosed |
| EP-1904451-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2008-04-02 | — | — | EP | disclosed |
| EP-1902032-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007125320-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125320-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2006136830-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136823-A1 | HETEROCYCLIC CONTAINING AMINES AS KINASE B INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136821-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136837-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| EP-1706385-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005061463-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | GAA 4851/4885MAPK1 180/4885KMT2A 1820/4885 |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | GAA 4851/4885MAPK1 180/4885KMT2A 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.